This brings the total amount raised by Vaccitech to £30 million since it was established in 2016. Vaccitech is commercialising the research of vaccine development specialists Adrian Hill and Sarah Gilbert, who developed the underpinning technology at the Jenner Institute.
Flu vaccine spinout secures a further £20m in funding
15 January 2018
Vaccitech, an Oxford University spinout company developing a universal flu vaccine has secured £20 million in Series A financing. The round was co-led by new investors GV, Sequoia China, and existing backer Oxford Sciences Innovation, which manages a £600m fund aimed at Oxford University spinouts, and was also joined by Neptune Ventures.